EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Artificial Intelligence as a Catalyst for Novel Therapeutic Opportunities in Precision Oncology

Kostas A Papavassiliou iD, Amalia A Sofianidi iD, Angeliki Margoni, Athanasios G Papavassiliou iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27198489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Kostas A Papavassiliou und 3 weiteren Autor:innen. Beteiligte Einrichtung: First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, 11527 …. Hauptthemen laut MEDLINE: Artificial Intelligence, Medical Oncology, Neoplasms, Precision Medicine. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence (AI) is reshaping molecular oncology by making complex biological data tractable and by extending the reach of precision drug discovery. Its emerging value is particularly evident at the interface of immunoengineering and targeted therapy, where computational models can help prioritize tumor-selective antigens, predict neoantigen immunogenicity, optimize engineered receptors, support antibody and antibody–drug conjugate design, guide small-molecule discovery, refine genome-editing strategies, and anticipate treatment response. Across these applications, the central promise is not automation for its own sake, but a wider therapeutic window in which tumor control is increased while off-target toxicity is reduced. Yet the translational gap remains substantial. Many models are still preclinical, external validation is limited, and clinical implementation remains uncommon. This Commentary follows representative methods across a therapeutic continuum that now extends from target discovery and therapeutic engineering to imaging, liquid biopsy, resistance forecasting, combination selection, and drug repurposing. We argue that clinical value will depend on closed-loop workflows in which multimodal predictions are experimentally validated, externally tested, and longitudinally updated to guide the next therapeutic decision.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceMedical OncologyNeoplasmsPrecision MedicineAnimalsHumansDrug Discovery

Stichwörter der Autor:innen

artificial intelligencedeep learningdrug discoveryimmunoengineeringmachine learningprecision oncology

Autor:innen und Institutionen

  • First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Kostas A Papavassiliou, Amalia A Sofianidi, Athanasios G Papavassiliou

Zitieren

APA

Papavassiliou, K. A., Sofianidi, A. A., Margoni, A., & Papavassiliou, A. G. (2026). Artificial Intelligence as a Catalyst for Novel Therapeutic Opportunities in Precision Oncology. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27198489

Vancouver

Papavassiliou KA, Sofianidi AA, Margoni A, Papavassiliou AG. Artificial Intelligence as a Catalyst for Novel Therapeutic Opportunities in Precision Oncology. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27198489

BibTeX
@article{Papavassiliou2026,
  author = {Papavassiliou, Kostas A and Sofianidi, Amalia A and Margoni, Angeliki and Papavassiliou, Athanasios G},
  title = {Artificial Intelligence as a Catalyst for Novel Therapeutic Opportunities in Precision Oncology},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27198489}
}
Kostenlos starten →